Confirmed and alleged misuses of flunitrazepam (FM2, Rohypnol) have brought about serious interest in the development of an analytical methodology that can be effectively used for preliminary screen and confirmatory test of FM2 (or its metabolites) in urine specimens under high.volume settings. Reported methods do not serve this need well for the following reasons: (1) common benzodiazepine (BZ) immunoassays (IAs) have broad cross-reactivities toward widely prescribed BZs (and their metabolites) and are therefore likely to generate an unacceptable number of false positives and (2) because FM2 is typically used at low doses (1-4 rag), IAs with low cross-reactivities toward FM2 (and its metabolites) are likely to generate false-negative results. In this current study, a familiar and effective two-step IA/gas chromatography-mass spectrometry (GC-MS) approach is successfully developed and applied to clinical specimens. Cross-reacting characteristics of the following BZ IAs toward various BZs (and their metabolites) are evaluated focusing on their effectiveness in serving as the preliminary test reagent in a two-step testing protocol: TDx ~, Beckman, CEDIA, Roche Cobas Integra, Emit ~ II Plus, and Cozart ELISA. Although other IAs show broad cross-reactivities toward various BZs and their metabolites, diazepam is the only non-FM2 derived compound that exhibits noticeable cross-reactivity toward Cozart ELISA reagent. Crossreactivity data and data derived from studies conducted on a limited number of clinical specimens demonstrate that, when used to monitor FM2 exposure in a large population group (including those exposed to other BZs), Cozart ELISA has the potential of being as effective as (or better than) those currently used in * Author to whom correspondence should be addressed.
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Introduction
Recent popularity of flunitrazepam (FM2, Rohypnol) in rave parties (1) , confirmed and alleged involvements in drugassisted sexual assaults (2) , and general interest in understanding its effects on human behavior and performance (3) bring about the need of a methodology that can be effectively used to analyze FM2 (or its metabolites) in urine specimens under high-volume settings.
Several immunoassays (IAs) (4, 5) and gas chromatography-mass spectrometry (GC-MS) (6-9) protocols have been used to study the excretion profiles of FM2 following its ingestion under controlled conditions. Both approaches (IA and GC-MS) can provide valuable information under this circumstance--limited number of specimens containing no other benzodiazepines (BZs). However, these IAs are likely to generate unacceptable numbers of false-positive and falsenegative results (see further discussion on these limitations in the Results and Discussion section), they cannot be used as an effective preliminary test method in a two-step test protocol for monitoring FM2 exposure in a large population group. This current study is designed to develop an effective two-step IMGC-MS approach for the analysis of the primary FM2 metabolite, 7-aminoflunitrazepam (7-amino-FM2), in urine under highvolume testing environment. Results hereby reported demonstrate that FM2 exposure in any large population group can be monitored with an efficiency that is equivalent to (or better than) those currently used in various workplace drug-testing programs for monitoring targeted drugs.
Materials and Methods

Reagents
Immunoassays for BZs (and manufacturers and reagent package insert dates) used in this study were TDx (Abbott Laboratories, Abbott Park, IL, 1996); Beckman (Beckman Instruments, Inc., Brea, CA, September 1995); CEDIA (Microgenics Co., Fremont, CA, April 2000); Cobas Integra (Roche Diagnostics Co., Indianapolis, IN, May 1998); Emit II Plus (Syva Co., Cupertino, CA, January 2000); and Cozart (Cozart Bioscience Ltd., Oxfordshire, U.K., September 2000). The targeted analytes adapted by various immunoassays are listed in Table I .
Benzodiazepines standards in 1 mg/mL (or 100 pg/mL) methanol solution purchased from Cerilliant Co. (Austin, TX) were used for cross-reactivity studies. 7-Amino-FM2 and 7-amino-FM2-d7 used as the calibrator and the internal standard in GC-MS analysis were also purchased from the same source.
Clinical specimens
Twenty-two specimens from two drug testing laboratories were included in this study. All specimens have previously been tested for BZs with the following results: 2 tested negative by Beckman, 9 tested positive by Beckman, and 11 tested positive by CEDIA. To explore the feasibility of excretion profile study, a series of 17 urine specimens have also been collected, following the administration of 2 mg FM2, from a patient who has no previous FM2 use record.
Immunoassay and GC-MS procedures
For IA testings, the procedures described in the respective reagent package inserts were followed using the calibrators provided by the respective manufacturers. For Cozart ELISA, all specimens were diluted with negative urine by a factor of 5 prior to testing.
For GC-MS analysis, urine specimens were adjusted to pH 9.0 (Na2CO3/NaHCO3 buffer) and extracted with ethyl acetate. 7-Amino-FM2 (if present) in the dried extract was then converted to its TMS-derivative using N-methyl-H-(trimethysilyl)-trifluoroacetamide as the derivatizing reagent.
A Hewlett-Packard (Palo Alto, CA) HP 5890 GC interfaced to a HP 5973N mass selective detector (MSD) was used to acquire full-scan and selected ion monitoring (SIM) mass spectrometric data. An HP-5MS capillary column (30 m x 0.25-ram i.d., 0.25-pro film thickness) was used with the following conditions: splitless injection; Helium flow rate, 0.6 mL/min; injection port, 260~ interface, 280~ column oven programming: starting at 150~ and holding for 1 rain, increasing to 300~ at 20~ then holding for 3.5 rain.
Full-scan mass spectra data ( Figure 1 ) were used to select analogous ion-pairs that were considered most suitable for the designation of the analyte and the internal standard. Ions selected for 7-amino-FM2 (as TMS-derivative) were m/z 355, 326, and 327; the corresponding ions for 7-amino-FM2-d7 (as TMS-derivative) were m/z 362, 333, and 334. The first ions (m/z 355 and 362) listed were used for quantitation. Limits of quantitation and detection are 5.0 and 2.5 ng/mL, respectively. Further details will be included in a later article devoted to various aspects of the confirmarion method developed for this and related compounds.
Results and Discussion
Immunoassays for preliminary test of flunitrazepam (or its metabolites)--current problem Included in Table I are the analytes targeted by BZ IAs commonly available in the U.S. and these IAs' cross-reactivities toward FM2 and its major metabolites (data taken from the reagent package inserts issued on the dates noted in the table).
As shown in Figure 2 (10), many BZs are biotransformed to oxazepam. Furthermore, all of these IAs have broad crossreactivities (data not shown) toward various BZs (and their metabolites) in addition to the targeted analytes. Because various BZs are widely prescribed, adapting these IAs (especially those using oxazepam as the targeted analyte) for the preliminary test is likely to generate an unacceptable number of false (11) .
A recent study reported a sensitive IA for FM2 and its metabolites (12) . Unfortunately, ELISA (enzyme-linked immunosorbent assay) kit used in this study could not be obtained. Instead, a highly specific (for 7-amino-FM2) ELISA from a different source (13) was found and adapted in this study. 
Calibration
In addition to the calibrators (0, 1, 5, and 25 ng/mL 7-amino-FM2) provided by the manufacturer, two sets of in-house standards (0, 1, 5, 10, 25, 50, 100, and 200 ng/mL 7-amino-FM2) were prepared and placed at two different sections of the 96-well plate. The resulting dose-response data derived from these two sets show slight difference (Figure 3) , presumably caused by random errors and slight variation in reaction time, which is a common problem associated with ELISA technology (14) . However, analyte concentration difference resulting from the use of these two calibration curves are not significant. It is clear, however, that the assay calibration is optimized at the 0-25 ng/mL range and becomes rather insensitive at higher concentrations.
Selection of targeted analyte for the detection of flunitrazepam exposure--cross-reactivity studies
Studies on the excretion profile of FM2 have well established 7-amino-FM2 as the primary urinary metabolite (4-6). Consequently, this compound has been widely used as the targeted analyte for the detection of FM2 exposure (7-9,15). Shown in Figure 4 are the cross-reactivities of five common IAs toward this compound. (Cross-reactivities are calculated by dividing the observed apparent concentration by the true concentration of the standard used in the study.) These IAs' crossreacting characteristics toward other BZs are compared to 7-amino-FM2 as shown in Figures 5-9 . These data clearly illustrate the non-specific nature of these reagents toward 7-amino-FM2; thus, their ineffectiveness in differentiating the presence of 7-amino-FM2 from other BZs. (The "hook effect" seen in the lower two parts of Figure 5 is probably artifacts resulting from the occurrence of detection saturation at the highest analyte concentration tested, 1000 ng/mL.)
On the contrary, Cozart ELISA shows practically no noticeable cross-reactivity toward most BZs (Table II) . Those showing cross-reactivities are FM2 (the parent compound), Ndesmethyl-FM2 (another metabolite of FM2), and an unrelated BZ (diazepam). Response data of these compounds at several concentration levels, derived from a four-point (0-, 1-, 5-, and 25-ng/mL calibrators provided by the manufacturer) calibration curve, are calculated and presented as percent cross-reactivities (Figure 10) . Thus, among the compounds studied (Table II and 
Applications
The effectiveness of Cozart ELISA is further evaluated in two applicational studies. The first study utilized specimens that are known to contain no other BZs. Specifically, a series of urine specimens collected from a known FM2 user under controlled conditions were analyzed using Cozart ELISA, Beckman, and CEDIA IAs and GC-MS. Apparent and true 7-amino-FM2 concentrations derived from these [As and the GC-MS procedures are shown in Table III and Figure 11 . These data indicate the following characteristics: (1) Beckman is least sensitive to detect the presence of 7-amino-FM2; (2) CEDIA is most sensitive in detecting the presence of 7-amino-FM2; however, its cross-reacting characteristics toward other BZs ( Figure 5 ) substantially reduce its effectiveness for monitoring FM2 exposure; and (3) Cozart generates responses that can be best related to the concentration of free 7-amino-FM2 as determined by the GC-MS protocol. The second study evaluates IAs' effectiveness as the preliminary test for the detection of FM2 exposure. Specifically, the following sets of urine specimens were included in this study: 2 true negatives; 9 previously tested positive for BZs by Beckman (cut-off: 200 ng/mL of the targeted analyte, oxazepam); and 11 previously tested positive for BZs by CEDIA (cut-off: 200 ng/mL of the targeted analyte, nitrazepam). All 22 specimens were tested by Cozart ELISA, Beckman, CEDIA, and GC-MS in the authors' laboratories. Data shown in Table IV demonstrate the following characteristics: (1) out of the 20 specimens that have previously been tested positive (using Beckman or CEDIA) for BZs, Cozart generates 5 results with apparent 7-amino-FM2 concentration higher than 50 ng/mL. Both Beckman and CEDIA reagents show much higher apparent 7-amino-FM2 concentrations for all specimens. (2) Only 2 specimens out of these 20 specimens were determined (by GC-MS) to contain free 7-amino-FM2 (182.1 and 44.2 ng/mL), of which the Cozart apparent 7-amino-FM2 concen-trations were 165.5 and 139.2 ng/mL, respectively.
These data appear to suggest that Cozart ELISA can be more effective than Beckman and CEDIA reagents when used for preliminary detection of FM2 exposure. Cozart ELISA test results, however, also included three "false positives" among the selected group of specimens shown in Table IV . The cause(s) for these false positives are not known, but presumably can derive from the presence of diazepam, which is known to produce up to 20% cross-reactivity (see Figure 10 ) and may present at a concentration much higher than 7-amino-FM2. Further study is needed to determine whether the interference of diazepam can be readily characterized without conducting GC-MS analysis.
Correlation of Cozart apparent and GC-MS true 7-amino-FM2 concentrations
As noted, the Cozart assay is optimized at the 0-25 ng/mL 7-amino-FM2 range. The assay's sensitivity is substantially reduced as the analyte's concentration becomes increasingly higher. With this in mind, test specimens were diluted by a factor of 5 to extent the assay's "dynamic range" up to approximately 125 ng/mL. Thus, Cozart data ( Table III) that are below this value represent valid estimates of the apparent 7-amino- FM2 concentrations in the respective test specimens, while those above this value were most likely underestimated. For the same reason, Cozart data for specimens 90134 and 90221 (Table W) most likely underestimated the apparent 7-amino-FM2 concentrations in these two specimens. With these limitations, it is still possible to relate the Cozart and GC-MS data shown in Table III and the two positive specimens included in Table IV . The following rationales may help understand the relationship between the data derived from these two methodologies: (i) for specimens 4-9 in Table III , Cozart data are not significantly higher than the GC-MS data. This may be an indication for the presence of the major portion of 7-amino-FM2 in its free form. (2) On the other hand, Cozart data are significantly higher in specimens 10-17 (Table III) . Perhaps a significant portion of 7-amino-FM2 are present as glucuronide (or other conjugates) or other metabolites as the metabolism process progressed further. (3) The relationship between the Cozart and the GC-MS data for specimen 90134 (Table IV) are compatible to those exhibited by the first group (specimens 4-9 in Table III ), while that for specimen 90221 (Table IV) is more like those exhibited by the second group (specimens 10-17 in Table III) .
These rationales may also explain why some studies found hydrolysis made insignificant increase in the amount of 7-amino-FM2 detected (8), whereas others reported otherwise (4) (5) (6) .
Having done a number of studies on the correlation of the apparent IA and the true GC-M8 analyte concentrations (16), we are interested in this subject matter for the 7-amino-FM2 system using Cozart ELISA kit and thought 50 ng/mL apparent 7-amino-FM2 in the undiluted specimen (i.e., 10 ng/mL following the dilution protocol) and 30 ng/mL free 7-amino-FM2 (GC-MS) might serve reasonably well as the preliminary test and confirmation test cut-offs. This proposal is based on the following considerations: (1) The relationship between the numerical data derived from the Cozart and GC-MS methodologies for specimens 10-17 in Table IlI; 
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TLme 00 afar intake of 2 nag flunitrazepam Figure 11 . Flunitrazepam excretion profiles following supervised intake of 2 mg flunitrazepam: apparent 7-amino-FM2 concentration (derived from a Cozart ELISA four-point calibration curve using the 0-, I-, 5-, and 25-ng/mL 7-amino-FM2 calibrators provided by the manufacturer) and free 7-amino-FM2 concentration as determined by GC-MS (without hydrolysis).
ion monitoring GC-MS technology; and (4) the amount of free 7-amino-FM2 observed at the late metabolism phase (Table  III) . Whether these values (50 and 30 ng/mL) are indeed good choices and whether free (instead of total) 7-amino-FM2 is an adequate analyte for GC-MS analysis can be better assessed when more comprehensive information in the following aspects become available: prevalence of 7-amino-FM2 in free and conjugate forms and cross-reacting characteristics of the conjugates.
Conclusions
Literature report (11) and cross-reactivity data provided by various manufacturers and derived from this study (TDx, Beckman, CEDIA, EMIT, Roche COBAS) strongly suggest that these IAs are not effective preliminary test reagents for monitoring FM2 exposure. Cross-reactivity and applicational studies of Cozart ELISA reagent have shown great potential when the following working parameters are considered: (1) Optimal semi-quantitative results can be achieved by diluting specimens by a factor of 5 prior to testing. (2) Based on the data derived from the limited number of specimens studied (Tables III  and IV) , a response equivalent to 10 ng/mL 7-amino-FM2 (as established by the calibrators provided by the manufacturer) can be used as an effective cutoff for the preliminary test (i.e., 50 ng/mL apparent 7-amino-FM2 prior to dilution). (3) 30 ng/mL free 7-amino-FM2 may serve well as the corresponding cut-off for the GC-MS confirmation test step.
A study on a significantly larger specimen population (collected from different individuals and various time intervals following the drug intake) is undoubtedly needed to better understand the relationship between the apparent and the true 7-amino-FM2 concentrations as determined by the Cozart EL~[SA and the GC-MS methodologies, respectively, and between the free and total 7-amino-FM2 concentrations in urine specimens collected from different individuals with different time intervals following the drug intake. Further study is also needed to determine whether false positives, caused by the presence of diazepam through cross-reactivity, can be readily characterized without conducting GC-MS analysis.
